IPO Market Unlocking for 'Omics-related Companies, but It's 'Anything but Robust' | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – For most of 2010, the IPO market froze out the life science tools and 'omics market, but by the end of the summer, there were signs that the public markets may be slowly welcoming firms operating in the space, as a handful of public offerings ended a cold snap.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.